This research service covers the therapeutics for rheumatic diseases market in the United States from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS); background standard of care therapies are not covered in this study. Included in the study are products already on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by disease indication: RA, PsA, and AS.